fosun pharma announces its results for the first three quarters of fiscal 2021 continues to strengthen commercialization capabilities net profit attributable to shareholders of the listed company increases by 43.80% yoy
in the first three quarters of 2021, fosun pharma adhered to the implementation of the “4in” strategy to alleviate the price downward pressure of products selected in the volume based procurement and achieved steady growth in the overall business performance. during the nine months ended september 30, 2021, fosun pharma achieved revenue of rmb27,048 million, representing an increase of 22.38% yoy; the net profit attributable to shareholders of the listed company amounted to rmb3,565 million, representing an increase of 43.80% yoy; the net profit attributable to shareholders of the listed company after deducting extraordinary gain or loss amounted to rmb2,475 million, representing an increase of 20.19% yoy.
continues to increase r&d investment and keeps enhancing the commercialization system
adhering to the development model of “innovation and transformation, integrated operation and steady development”, fosun pharma keeps enhancing innovative r&d and bd capabilities, enriching product lines, promoting the development of innovative products and technologies, as well as consolidating the commercialization system. in the first three quarters of 2021, fosun pharma’s r&d expenditure amounted to rmb3,151 million, representing an increase of 15.46% yoy. in particular, the r&d expenses was rmb2,414 million, representing an increase of 28.54% yoy.
comirnaty® (mrna covid-19 vaccine, also known as bnt162b2) has been included in the government vaccination programs in hong kong sar and macau sar. after signing the sales agreement in july 2021, the supply and vaccination have started in late september 2021 in taiwan region. as of 24 october 2021, more than 9.7 million doses of bnt162b2 have been vaccinated in hong kong sar, macau sar, and taiwan region.
since its launch in june 2021, yi kai da (axicabtagene ciloleucel injection) of fosun kite, has been exploring diversified payment methods and has been covered by public-interest insurance in cities like changsha, suzhou, to improve the product's accessibility and benefit more patients. at the same time, the second indication of yi kai da (for the treatment of relapsed or refractory non-hodgkin’s lymphoma (r/r inhl) after two or more lines systemic therapy) was granted breakthrough therapy designation by the national medical products administration (nmpa) in august 2021.
fosun pharma continues to enhance the r&d and commercialization of biopharmaceuticals. xuhui facility passed the gmp compliance on-site inspection for the production of serplulimab injection (recombinant humanized anti-pd-1 monoclonal antibody injection). the new drug application of serplulimab’s second indication was accepted by the nmpa in september 2021. the new addition of the specification of 60mg/vial of trastuzumab injection (han qu you®) was approved, further enriching the list of medicine choices.
improves international operation capability and promotes global presence actively
while increasing investment in innovative r&d, fosun pharma continues to improve its international operation capability and promote global presence actively. on 14 october 2021 cote d’ivoire local time, the group’s subsidiary tridem pharma opened its first african regional distribution hub in côte d’ivoire, optimizing its supply chain capability in africa. in the future, tridem pharma’s pharmaceutical distribution hub in côte d'ivoire will be a good approach for the continuous accessibility of pharmaceutical and healthcare products in africa.
wu yifang, chairman and ceo of fosun pharma said: “fosun pharma practices innovation and transformation, integrated operation and steady development, as well as the concept of sustainable development. took innovation and internationalization as its core drivers, as well as increasing its r&d investment, fosun pharma will accelerate the development of innovative drugs and enhance clinical capability through in-house r&d, co-development, in-licensing and incubation. fosun pharma will keep promoting the development and transformation of innovative technologies and products, committing to becoming the first-class enterprise in the global mainstream healthcare industry.”